제품 세부정보
FAB
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human IL-23 / IL-23R Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human IL-23 binding to human IL-23R within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of human IL-23 to bind to human IL-23R.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP010-C01Human IL-23 alpha&IL-12 beta Heterodimer Protein Europium-chelate100 tests/500 testsFRTP010-C02FA Labeled Human IL-23R100 tests/500 testsFRTP010-C03Anti-IL23A Neutralizing Antibody30 μg/100 tests 150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human IL-23 / IL-23R Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated IL-23 alpha&IL-12 beta and Europium-chelate labeled streptavidin as the donor and FA labeled human IL-23 R as the acceptor.
— In the absence of inhibitors for human IL-23 R binding to IL-23 alpha&IL-12 beta, the donor and acceptor are in close proximity due to the binding of human IL-23 R and IL-23 alpha&IL-12 beta. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
— In the presence of inhibitors that block the binding of human IL-23 R to IL-23 alpha&IL-12 beta,the donor-acceptor interaction is disrupted, preventing FRET from occurring.

ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.

Inhibition of Europium-chelate labeled Human IL-23 alpha&IL-12 beta Heterodimer Protein : FA Labeled Human IL-23R binding by Anti-IL23A Neutralizing Antibody
Premix serial dilutions of Anti-IL23A Neutralizing Antibody (1:2 serial dilution, from 10 μg/mL to 0.01 μg/mL (66.67-0.07 nM)) and Human IL-23 alpha&IL-12 beta Heterodimer Protein Europium-chelate. Then add FA Labeled Human IL-23R and incubate at room temperature (20℃-25℃) for 1 hours. Detection was performed with IC50 of 1.737nM. The assay was performed according to the above-described Datasheet (QC tested).
사용자 리뷰 댓글 남기기

프론티어 진행
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

















